VI 16832
目录号 : GC32833
VI16832是一种广谱的I型激酶抑制剂，可用作不同癌细胞系中蛋白激酶比较表达分析的富集工具。
Cas No.:1430218-51-1
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >99.50%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Kinase experiment: | Cells are lysed in a volume of 35 to 40 mL per experiment. The protein amounts of the starting extracts used in the first and second experiments are: 435S, 85 and 120 mg; HCT116, 240 and 175 mg; MV4-11, 180 and 120 mg. Lysates are adjusted to 1 M NaCl prior to loading onto the VI 16832 column at a flow rate of 0.07 mL/min. Subsequent washing and elution steps are performed. Protein-containing elution fractions are lyophilized, resuspended in one tenth of the initial volume, and then desalted by protein precipitation prior to gel electrophoresis[2]. |
References: [1]. Kyla. A. L. Collins, et al. Proteomic Analysis Defines Kinase Taxonomies Specific for Subtypes of Breast Cancer. Apr. 1, 2017. | |
VI 16832 is a broad spectrum Type I kinase inhibitor which can be used as an enrichment tool for the comparative expression analysis of protein kinases in different cancer cell lines.
VI 16832 is a broad spectrum Type I kinase inhibitor[1]. Phosphoproteomics analysis of VI 16832-enriched fractions from MV4-11, HCT116, or 435S cells results in more than 8500 phosphopeptide identifications. These translate into almost 1700 distinct phosphopeptide species derived from 212 different members of the protein kinase superfamily. Analysis of VI 16832-retained proteins from the three cancer cell lines considerably increases the overall number of identified phosphorylation sites on protein kinases. Considering the sum of all phosphopeptide intensities as a measure for VI 16832-enriched protein amount, more than 80% is derived from protein kinases[2].
[1]. Kyla. A. L. Collins, et al. Proteomic Analysis Defines Kinase Taxonomies Specific for Subtypes of Breast Cancer. Apr. 1, 2017. [2]. Felix S. Oppermann, et al. Large-scale Proteomics Analysis of the Human Kinome. Mol Cell Proteomics. 2009 Jul; 8(7): 1751-1764.
| Cas No. | 1430218-51-1 | SDF | |
| Canonical SMILES | O=C1C=CC2=CN=C(NC3=CC=C(OCCN)C=C3)N=C2N1C4C(C5)CCC5C4 | ||
| 分子式 | C22H25N5O2 | 分子量 | 391.47 |
| 溶解度 | DMSO : 83.3 mg/mL (212.79 mM) | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 2.5545 mL | 12.7724 mL | 25.5447 mL |
| 5 mM | 0.5109 mL | 2.5545 mL | 5.1089 mL |
| 10 mM | 0.2554 mL | 1.2772 mL | 2.5545 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。